When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Paxneury and Tuzulby should be granted Europe-wide marketing authorizations for treating attention-deficit hyperactivity, the ...
The European Medicines Agency (EMA) has given a positive recommendation for Rytelo ( imetelstat) for the treatment of adult ...
2d
Semaglutide use in diabetes patients is linked to a higher risk of NAION, a rare eye condition. A Danish-Norwegian study ...
The European Medicines Agency has allowed Eli Lilly to update the product label of its weight-loss drug Mounjaro to show it ...
Novo Nordisk's Ozempic will become the first and only GLP-1 drug to be shown to reduce progression of kidney disease in ...
Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...
Eli Lilly (NYSE: LLY) has received a positive recommendation for approval from European regulators for its drug Omvoh in the ...
Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with ...
Eli Lilly on Friday said the recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use covers Omvoh for the treatment of adults with moderately to severely ...
Eli Lilly (LLY) and Company announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback